Method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (IECT)

Method for prevention or treatment of side effects of immune effector cell therapy (IECT) in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), wherein the treatment is immunosuppressive therapy, wherein said patient is selected by a method comprising the steps:

• determining at least one endothelial dysfunction biomarker in a sample of bodily fluid obtained from said patient and
• correlating said level of at least one endothelial dysfunction biomarker in said sample to said risk of side effects, and
• wherein said side effects are selected from the group comprising cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).

Medicament for use in the prevention or treatment of side effects of immune effector cell therapy (IECT) in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), wherein said patient is selected by a method comprising the steps:

• determining at least one endothelial dysfunction biomarker in a sample of bodily fluid obtained from said patient and
• correlating said level of at least one endothelial dysfunction biomarker in said sample to said risk of side effects, and
• wherein said side effects are selected from the group comprising cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS), and wherein said medicament is an immunosuppressive medicament.

A method for patient stratification and/or selection of a patient for treatment of side effects, wherein said patient is a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), said method comprising:

• determining the level of at least one endothelial dysfunction biomarker in a sample of bodily fluid of said patient and
• assigning if said patient is to receive treatment of said side effects based on said level of at least one endothelial dysfunction biomarker in said sample.